Silencing IncRNAs PVT1 Upregulates miR-145 and Confers Inhibitory Effects on Viability, Invasion, and Migration in EC

Si-Ning Shen,1 Ke Li,2 Ying Liu,3 Cheng-Liang Yang,3 Chun-Yu He,3 and Hao-Rang Wang1

Long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) is correlated to various malignant tumors. Consequently, we explored effects of lncRNA PVT1 on esophageal carcinoma (EC) targeting microRNA-145 (miR-145). EC tissues, adjacent normal tissues, and EC-related cell lines were collected and cultured. Expression of lncRNA PVT1, miR-145, fascin-1 (FSCN1), and related genes with intervening expression of PVT1 and miR-145 was determined. Bioinformatic website, dual-luciferase reporter assay, and RNA immunoprecipitation (RIP) were carried to verify target relationship among lncRNA PVT1, FSCN1, and miR-145. Scratch test, Transwell assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and flow cytometry were performed for detection of migration, invasion, viability, and apoptosis of transfected cells, respectively. Finally, tumor formation in nude mice was measured. After database analysis, lncRNA PVT1, miR-145, and FSCN1 were selected for study. lncRNA PVT1 and FSCN1 can bind to miR-145. After overexpressing miR-145 or inhibiting lncRNA PVT1, EC cell viability, migration, and invasion were inhibited, while volume and weight of tumor formation in nude mice decreased. Expression of lncRNA PVT1, FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 decreased and expression of miR-145 and Bax increased. Silencing lncRNA PVT1 can upregulate miR-145, which is a tumor suppressor in EC via knockdown of FSCN1. Thus, we might provide a potential theoretical basis for EC treatment.

INTRODUCTION

Esophageal carcinoma (EC) is a common malignant gastrointestinal tumor and one of the main reasons for tumor-related death.1 It has been estimated that in 2012, 455,800 patients were newly diagnosed with EC and 400,200 EC-related deaths occurred globally.2 Smoking, drinking, and high body mass index are the risk factors for EC, and it has been validated that the ingestion of vegetables and fruits can reduce the morbidity of EC.3 Although surgery along with radiotherapy and chemotherapy to treat EC has developed in the past years, the entire survival rates within 5 years are still under 20% due to the high possibilities of recurrence and distant metastasis of EC.4,5 Anastomotic leaks and pulmonary complications are the most common post-operative complications of EC.6 Numerous microRNAs (miRNAs) have been verified to be located at cancer-related delicate sites and genomic regions, which suggests that miRNAs play roles in the pathogenesis of human cancers.7 miR-145 is a tumor suppressor found in various cancers like breast cancer,8 lung cancer,9 colon cancer,10 and gastric cancer.11 miR-145 promotes glioma cell apoptosis by suppressing BNIP3, leading to inactivation of Notch signaling pathway.12 And upregulation of miR-145 reduces proliferation and metastasis of EC.13 Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nt, and some lncRNAs are verified to be implicated in different processes of malignant tumor development, such as carcinogenesis, progression, and metastasis.14 lncRNA plasmacytoma variant translocation 1 gene (PVT1) is a well-studied lncRNA that can affect apoptosis, migration, and invasion, as well as proliferation.15 And lncRNA PVT1 plays oncogenic roles in prostate cancer.16 Zhuang et al.18 found that upregulation of PVT1 promoted cell proliferation and suppressed cell apoptosis in bladder cancer. lncRNA-UCA1 upgrades cell migration and invasion by the hsa-miR-145-zinc finger E-box binding homeobox 1/2 (ZEB1/2)-fascin homolog 1 pathway in bladder cancer.19 Fascin-1 (FSCN1) is an actin bundling protein that is implicated in cancer metastasis and recurrence through regulating cellular proliferation and clon ing efficiency.20 It has been demonstrated that overexpression of miR-145 can reduce cancer migration through regulating FSCN1.21 We intend to investigate regulatory roles of lncRNA-PVT1, miR-145, and FSCN1 in EC.

Received 11 December 2018; accepted 23 November 2019;
https://doi.org/10.1016/j.omtn.2019.11.030.
Correspondence: Si-Ning Shen, PhD, Department of Thoracic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou 450008, Henan Province, P.R. China.
E-mail: shen_sining@126.com

Correspondence: Cheng-Liang Yang, Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou 450008, Henan Province, P.R. China.
E-mail: yangchli2@163.com

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The Expression of lncRNA PVT1 Was High in EC Issues
(A) Wayne chart of top 100 differential genes of chips GSE23400, GSE38129, and GSE77861. (B) Expression level of FSCN1 on GSE20347. (C) Expression level of FSCN1 on TCGA database. (D) Target of FSCN1 on four bioinformatics. (E) Expression level of mir-145 on TCGA database. (F) Thermal map of chip GSE45168. (G) Expression level scatter diagram of PVT1 on TCGA database. (H) expression of lncRNA PVT1 in cancer tissues and adjacent normal tissues detected by qRT-PCR. Statistical values were the measurement data and expressed as mean ± standard deviation. t test was used to conduct data analysis, n = 50. (I) Expression of PVT1 in cell
RESULTS

IncRNA PVT1 and FSCN1 Are Highly Expressed in EC Issues

MMP1, GPD1L, KAT2B, and FSCN1 were expressed differently in EC from EC chips GSE23400, GSE38129, and GSE77861 (Figure 1A). Chips GSE20347 and The Cancer Genome Atlas (TCGA) database were used to co-verify that only FSCN1 was highly expressed in EC (Figures 1B and 1C). It was found that FSCN1 could be the target gene of hsa-miR-429, hsa-miR-200c-3p, hsa-miR-488-3p, hsa-miR-145-5p, hsa-miR-429, hsa-miR-200c-3p, hsa-miR-488-3p, hsa-miR-145-5p, hsa-miR-200b-3p, and hsa-miR-24-3p based on the websites (http://www.microrna.org/microrna/microrna/getMirnaForm.do), mirdb.org (http://www.mirdb.org/), starbase (http://starbase.sysu.edu.cn/index.php), and targetscan.org (http://www.targetscan.org/vert_71/) (Figure 1D). TCGA database showed that only hsa-miR-145-5p was poorly expressed in EC (Figure 1E). It was verified that PVT1 could bind to hsa-miR-145-5p according to websites RAID v2.0 (http://www.rna-society.org/raid/index.html) and mircode.org (http://www.mircode.org/), and IncRNA PVT1 was highly expressed in EC based on chip GSE45168 and TCGA database (Figures 1F and 1G). qRT-PCR (Figure 1H) revealed that compared with adjacent normal tissues, the expression of IncRNA PVT1 in EC tissues was increased (p < 0.05). As shown in Figure 1I, compared with normal epithelial cell line HHEC, the expression of IncRNA PVT1 in cell lines KYSE-30, KYSE-70, KYSE-109, Eca109, and TE-1 were increased (p < 0.05). KYSE-30 cell line was selected.

Expression of IncRNA PVT1, EC-Related Genes, and miR-145 Was Measured in EC Tissues

Expression of IncRNA PVT1, miR-145, and EC-related genes in EC tissues was determined by qRT-PCR (Figures 2A and 2B). In the IncRNA PVT1 related groups, the blank group and the negative control (NC) group exhibited no significant difference (p > 0.05). Compared with the blank group and the NC group, the expression of IncRNA PVT1, FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the IncRNA PVT1 mimic group were increased (p < 0.05), and expression of Bax and miR-145 were decreased. The expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the small interfering IncRNA (si-lncRNA) PVT1 group were decreased (p < 0.05), and the expression of Bax and miR-145 were increased obviously (p < 0.05). In the miR-145 related groups, no significant differences were found in the blank group and the NC group; compared with the blank group and the NC group, the expression IncRNA PVT1, FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the miR-145 mimic group and the si-FSCN1 group were decreased (p < 0.05) and the expression of Bax and miR-145 were increased (p < 0.05). In the miR-145 inhibitor group, the expression of IncRNA PVT1, FSCN1, Bcl-2, CD147,

![Figure 2. The Expression of IncRNA PVT1, miR-145, and EC-Related Genes in EC Tissues](image-url)
VEGFR2, and MTA1 were increased and the expression of Bax and miR-145 were decreased (p < 0.05). No obvious difference was found in the miR-145 inhibitor + si-FSCN1 group (p > 0.05). The above results showed that lncRNA PVT1 and EC-related genes were highly expressed, whereas miR-145 was poorly expressed in EC tissues.

Expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 were increased and the expression of Bax was decreased (p < 0.05). The results of western blot analysis were count data and were expressed as mean ± standard deviation. One-way ANOVA was adopted to analyze index and data comparison among groups. The experiment was repeated three times; *, versus the blank group, p < 0.05; #, versus the NC group, p < 0.05; IncRNA, long non-coding RNA; EC, esophageal carcinoma; miR-145, microRNA-145; PVT1, plasmacytoma variant translocation 1 gene; one-way ANOVA, one-way analysis of variance; NC, negative control.

Expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 were measured at protein level in EC tissues

Expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 were measured at protein level in EC tissues. (A and B) Expression of EC-related genes determined by western blot analysis with silencing or overexpressing lncRNA PVT1. (C and D) Expression of EC-related genes determined by western blot analysis with silencing of miR-145. The results of western blot analysis were count data and were expressed as mean ± standard deviation. One-way ANOVA was adopted to analyze index and data comparison among groups. The experiment was repeated three times; *, versus the blank group, p < 0.05; #, versus the NC group, p < 0.05; IncRNA, long non-coding RNA; EC, esophageal carcinoma; miR-145, microRNA-145; PVT1, plasmacytoma variant translocation 1 gene; one-way ANOVA, one-way analysis of variance; NC, negative control.

Figure 3. Expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 at Protein Level

In the lncRNA PVT1 related groups, the blank and NC groups retained similar trends (p > 0.05); compared with the blank group and the NC group, the expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the lncRNA PVT1 mimic group were increased (p < 0.05) and expression of Bax was decreased. The expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the si-lncRNA PVT1 group were decreased (p < 0.05), and the expression of Bax was increased obviously (p < 0.05). In the miR-145 related groups, results in the blank and NC groups remained similar; compared with the blank group and the NC group, the expression of lncRNA PVT1, FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 in the miR-145 mimic group and the si-FSCN1 group were decreased (p < 0.05) and the expression of Bax was increased (p < 0.05). In the miR-145 inhibitor group, the expression of lncRNA PVT1, FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 were increased, and the expression of Bax was decreased (p < 0.05). The expression of those genes remained similar in the miR-145 inhibitor + si-FSCN1 group (p > 0.05). Protein levels of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 were downregulated and that of Bax was upregulated when lncRNA PVT1 or FSCN1 was silenced overexpression or miR-145 was overexpressed.

lncRNA PVT1 Specifically Binds to miR-145

FTSH, bioinformatic analysis, and dual-luciferase reporter assay were carried to explore interaction between lncRNA PVT1 and miR-145.
Analysis on the online prediction websites suggested that lncRNA PVT1 (Homo sapiens) was mainly located in cytoplasm, which was confirmed by fluorescence in situ hybridization (FISH) in human tissues (Figures 4A and 4B). The online analysis software predicated that there were specific binding regions between lncRNA PVT1 sequence and miR-145 sequence (Figure 4C). Dual-luciferase reporter assay showed that compared with the NC mimic group, luciferase activity of the lncRNA PVT1 in the miR-145 mimic group was decreased (p < 0.05), while the luciferase activity of lncRNA PVT1 MUT between the NC mimic group and miR-145 mimic group remained similar (p > 0.05), which verified that lncRNA PVT1 bound to miR-145 (Figure 4D).

miR-145 Specifically Binds to FSCN1 Gene

Bioinformatic analysis and dual-luciferase reporter assay were used to probe the target relationship between miR-145 and FSCN1. The online analysis software microRNA.org showed that there were specific binding regions between FSCN1 sequence and miR-145 sequence, indicating that FSCN1 might be the target gene of miR-145 (Figure 5A). Dual-luciferase reporter assay showed that compared with the NC group, luciferase activity of the FSCN1 in the miR-145 mimic group was decreased (p < 0.05); no significant differences were found in the luciferase activity of FSCN1 MUT between NC mimic group and miR-145 group (p > 0.05), which verified that FSCN1 was a target of miR-145 (Figure 5B).

IncRNA PVT1 Negatively Regulates miR-145 Expression

RNA-pull down and RNA immunoprecipitation (RIP) (co-immunoprecipitation assays) verifying interaction between IncRNA PVT1 and miR-145 (Figures 6A–6D) suggested that the level of IncRNA PVT1 was higher in the IncRNA PVT1-WT (wild-type) group and lower in the IncRNA PVT1-MUT (mutant) group and the level of miR-145 was higher in the miR-145-WT group and lower in the miR-145-MUT group (all p < 0.05). Western blot analysis revealed that miR-145 was poorly expressed in the miR-145-WT group and highly expressed in the IncRNA PVT1-MUT group and IncRNA PVT1 was poorly expressed in the miR-145-WT group and highly expressed in the miR-145-MUT group (all p < 0.05). The above results demonstrated that IncRNA PVT1 negatively regulated the expression of miR-145.

Downregulation of IncRNA PVT1 Inhibits Viability of EC Cells

In order to detect the viability of EC cells in each group, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was then conducted (Figures 7A and 7B). In IncRNA PVT1-related groups, there were no obvious differences in cell viability between
the blank group and the NC group at each time point (p > 0.05). But compared with the blank group and the NC group, cell viability in the lncRNA PVT1 mimic group was increased (p < 0.05) and cell viability in the si-lncRNA PVT1 group was decreased obviously (p < 0.05). In the miR-145 related groups, there were no obvious differences in cell viability between the blank group and the NC group at each time point (p > 0.05). Compared with the blank group and the NC group, cell viability in the miR-145 mimic group and the si-FSCN1 group was decreased (p < 0.05) and cell viability in the miR-145 inhibitor group was increased (p < 0.05); no obvious differences in the cell viability were found in the miR-145 inhibitor + si-FSCN1 group (p > 0.05). The results above demonstrated that suppression of lncRNA PVT1 or miR-145 could increase viability of EC cells.

**Downregulation of lncRNA PVT1 Promotes Apoptosis and Arrests Cells in G1 Phase**

Scratch test was carried out to determine effect of silenced lncRNA PVT1 and miR-145 on migration of EC cells (Figures 8A–8D). In lncRNA PVT1 related groups, no obvious differences were found in the blank and NC groups (p > 0.05). But compared with the blank group and the NC group, cell migration in the lncRNA PVT1 mimic group was increased (p < 0.05) and cell migration in the si-lncRNA PVT1 group was decreased obviously (p < 0.05). In the miR-145 related groups, no obvious differences in cell migration were found between the blank group and the NC group (p > 0.05). But compared with the blank group and the NC group, cell migration in the miR-145 mimic group and the si-FSCN1 group was decreased obviously (p < 0.05). No obvious differences in cell migration were found in the miR-145 inhibitor + si-FSCN1 group (p > 0.05). Results of Transwell assay showed that inhibition of lncRNA PVT1 and si-FSCN1 or overexpression of miR-145 could inhibit invasion.

**Downregulation of miR-145 Inhibits Apoptosis and Arrests Cells in G1 Phase**

Propidium iodide (PI) staining and Annexin V-PI double staining were used to detect cell cycle and cell apoptosis, respectively. As shown in Figures 10A–10D, in the lncRNA PVT1 related groups, no obvious differences in cell apoptosis were found between the blank group and the NC group (p > 0.05). Compared with the blank group and the NC group, the lncRNA PVT1 mimic group, fewer cells were arrested in G1 phase, more cells were arrested in S phase, and apoptosis rate increased (p < 0.05). The above results proved that inhibition of lncRNA PVT1 increased apoptosis and promoted transition of cell cycle from G1 phase to S phase.

**Downregulation of miR-145 Inhibits Apoptosis and Arrests Cells in S Phase**

PI staining and Annexin V-PI double staining were used to detect cell cycle and cell apoptosis, respectively. As shown in Figures 11A–11D, in the miR-145 related groups, no obvious differences in cell apoptosis were found between the blank group and the NC group (p > 0.05). Compared with the blank group and the NC group, in the miR-145 mimic group and the si-FSCN1 group, more cells were arrested in G1 phase, fewer cells were arrested in S phase, and apoptosis rate increased (p < 0.05); in the miR-145 inhibitor group, apoptosis rate decreased (p < 0.05). In the si-lncRNA PVT1 group, more cells were arrested in G1 phase, fewer cells were arrested in S phase, and apoptosis rate increased (p < 0.05). The above results proved that inhibition of lncRNA PVT1 increased apoptosis and promoted transition of cell cycle from G1 phase to S phase.

**Figure 5. FSCN1 Is a Target Gene of miR-145**

(A) Specific binding regions between FSCN1 sequence and miR-145 sequence was detected by the online analysis software [microRNA.org](http://www.mirbase.org). (B) Dual-luciferase reporter assay verified that FSCN1 was the target of miR-145. The values of luciferase activity were count data and expressed as mean ± standard deviation. Unpaired t test was applied to analyze data between two groups. The experiment was repeated three times; *, versus the NC group, p < 0.05; miR-145; microRNA-145; FSCN1, fascin actin-bundling protein 1; NC, negative control.
Inhibition of miR-145 suppressed apoptosis and inhibited transition of cell cycle from G1 phase to S phase.

**Downregulation of lncRNA PVT1 Inhibits the Development of EC**

Tumor formation in nude mice was observed to examine the effects of lncRNA PVT1 on the development of EC. As shown in Figures 12A–12C, in the lncRNA PVT1 related groups, no obvious difference was found in the blank and NC groups (p > 0.05). Compared with the blank group and the NC group, the tumor volume and weight were increased in the lncRNA PVT1 mimic group (p < 0.05) and decreased in the si-lncRNA PVT1 group (p < 0.05). In the miR-145 related groups, no obvious differences in volume and weight of nude mice tumor were found between the blank group and the NC group (p > 0.05). Compared with the blank group and the NC group, the tumor volume and weight of nude mice were decreased obviously in the miR-145 mimic and the si-FSCN1 group (p < 0.05), increased obviously in the miR-145 inhibitor group (p < 0.05), and exhibited no obvious difference in the miR-145 inhibitor + si-FSCN1 group (p > 0.05). The above results suggested that inhibition of lncRNA PVT1 or FSCN1 and upregulating miR-145 inhibited the development of EC.

**DISCUSSION**

Poor outcomes in patients with EC are related with diagnoses at advanced stages and the tendency for metastases; thus, it requires further investigation on the potential mechanisms of EC progression. It has been revealed that miRNAs and IncRNAs exert functions on EC. The present study explored the mechanism of how IncRNA PVT1 and miR-145 function in EC cells. Consequently, we found that silencing IncRNA PVT1 upregulated miR-145 and conferred inhibitory effects on viability, invasion, migration, and stimulative effects on apoptosis of EC through knockdown of FSCN1.

Initially, western blot analysis and qRT-PCR showed that miR-145 was poorly expressed, but IncRNA PVT1 and FSCN1 were highly expressed in EC. miR-145 was downregulated in many human cancer types, including gastrointestinal tract, lung, and gallbladder cancer. It has been validated that IncRNA AK001796 could act as an effective treatment target and underlying prognostic factor for ESCC. Interestingly, Wu et al. also found that overexpressed IncRNA PVT1 was related with tumorigenesis and poor prognosis in cancers. In addition, FSCN1 was expressed at a high level in ESCC, and overexpression of FSCN1 led to poor prognosis in ESCC. Similarly, research on ESCC-CHU18 showed that miR-145 downregulated FSCN1 and the aberrant expression of IncRNA promoted the expression of FSCN1.

Expression of FSCN1, Bcl-2, CD147, VEGFR2, and MTA1 was downregulated and expression of Bax was upregulated with silencing IncRNA PVT1 or FSCN1 and upregulating miR-145. Knockdown of IncRNA PVT1 elevated expression of Bax and decreased that of anti-apoptotic factor Bcl-2. VEGFs regulated vascular development, lymphangiogenesis, and angiogenesis by binding to various receptors, among which VEGFR-2 could influence cell viability, migration, and survival. Silencing VEGFR2 could promote cell development and angiogenesis in mouse models of pancreatic ductal adenocarcinoma, and upregulation of miR-200 led to decreasing of VEGFR2. MTA1 acts as a tumor metastasis-related gene, whose expression was found higher with the increasing stage of ESCC. Overexpression of CD147 could promote invasion and lymph node metastasis, and CD147 was upregulated with the increasing stage of ESCC. Overexpression of miR-145 decreased FSCN1 expression, which was the same as findings by dual-luciferase reporter assay.

Our findings also revealed that silencing IncRNA PVT1 upregulated miR-145 and inhibited the viability, migration, invasion capacity, and induced apoptosis of EC cells via inhibition of FSCN1. It was also validated that overexpressing miR-145 could suppress non-small cell lung cancer cell growth, migration, and invasion, partially by suppressing FSCN1 expression. Sheng et al. indicated that aberrant expression of miR-145 dampened migration and invasion of colorectal cancer cells. Likely, overexpression of miR-133b in ESCC cell lines inhibited viability and accelerated apoptosis. Interestingly, overexpression of miR-129 led to a marked suppression on cell viability and invasion capacity of ESCC. Downregulation of FSCN1 decreased gastric cancer cell viability and metastasis. IncRNA PVT1 functioned as a tumor-promoter in cancer development, whose knockdown expressively reduced viability, migration, and invasion and enhanced apoptosis of cervical cancer cells. Restored IncRNA PVT1 promoted cell invasion by accelerating epithelial-to-mesenchymal transition in EC. Also, downregulation of IncRNA PVT1 could suppress viability and induce apoptosis of renal cancer cells. Similarly, it was validated that silencing IncRNA
CASC9 suppressed migration and invasion of EC in vitro. These results suggested that downregulation of IncRNA PVT1 can induce the overexpression of miR-145 thus inhibiting cell viability, migration, and invasion, affecting cell cycle and accelerating apoptosis of EC via knockdown of FSCN1.

Consequently, our study demonstrated that silencing of IncRNA PVT1 can promote the expression of miR-145, thus it can function as a tumor suppressor in EC cells through downregulating FSCN1 (Figure 13). Our research might provide novel insight for the molecular mechanism of EC.

MATERIALS AND METHODS

Ethics Statement

This experiment was based on the premise of safeguarding the interests of the subjects. The subjects were fully informed and agreed to donate the diseased materials to the laboratory after ethical review.

Co-analyze the Differential Expression of IncRNA, mRNA, and miRNA in ECs Based on GEO Database and TCGA Database

EC-related chips expression profile data (GEO: GSE23400, GSE38129, GSE77861, and GSE45168) and note probe files were downloaded from GEO database (http://www.ncbi.nlm.nih.gov/geo). Affy install pack of R software was used to revise the background and conduct normalization processing of each chip. Then, linear model in the Limma install pack of R was performed for the transcriptome profiling data with package edgeR of R. False positive discovery (FDR) correction was applied on p value with package multtest. FDR < 0.05 and \( \log_2 \) (fold change) > 1 were set as the threshold to screen out DEGs (differentially expressed genes). MicroRNA.org, mirdb.org, starbase, and targetscan.org were used to predict the target gene of miRNA. RAID v2.0 website and mircode.org website were used to analyze lncRNA that binds to miRNA.

Figure 7. Viability of EC Cells Was Inhibited via Suppression of IncRNA PVT1 and si-FSCN1, as well as Overexpression of miR-145

(A and B) Cell viability determined by MTT assay; overexpression results value of viability capacity in each group after transfection were count data and were expressed as mean ± standard deviation. Variance analysis which was measured repeatedly was adopted. The experiment was repeated three times; *, versus the blank group, \( p < 0.05 \); #, versus the NC group, \( p < 0.05 \); IncRNA, long non-coding RNA; miR-145, microRNA-145; PVT1, plasmacytoma variant translocation 1 gene; NC, negative control.

Subjects and Cell Culture

EC tissues and adjacent normal tissues of 50 EC patients (31 male and 19 female) aged 34–72 who got surgical treatments from October 2016 to June 2017, in the Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital were collected. The EC tissues were collected, and adjacent normal tissues were taken from the normal mucosal tissues at the margin of the tumor, which can be observed by naked eye and from atypical hyperplasia tissues non-stained by Lugol’s dye. EC specimens removed surgically were placed under aseptic condition immediately and put into the aseptic eppendorf (EP) tube free of RNase. The tube was put into nitrogen canisters immediately and preserved in a refrigerator at \(-80^\circ C\). The study enrolled human EC cell lines KYSE-30, KYSE-70, KYSE-109, Eca109, TE-1, and normal esophageal epithelial cell line HEEC (Shanghai Institute of Biochemistry and Cellular Biology, Chinese Academy of Sciences, Shanghai, China). Each cell line was cultured in the 5 mL/dL CO\(_2\) incubator at 37\(^\circ\)C with RPMI 1640 medium (GIBCO, Grand Island, NY, USA) containing 10 g/dL fetal bovine serum (FBS) (Jiangsu Kunt Biological, Chanzhou, Jiangsu, China). When cells reached 80%–90% confluence, they were passaged using 0.25 g/dL trypsin (Shanghai Regal Biology Technology, Shanghai, China).

Plasmid Construction, Cell Grouping, and Transfection

According to the sequences of IncRNA PVT1, miR-145, and FAS searched from NCBI, the blank, IncRNA PVT1 mimic, IncRNA PVT1 NC, si-IncRNA PVT1, miR-145 NC, miR-145 mimic, anta-miR-145 NC and miR-145 inhibitor, si-FSCN1, and miR-145 inhibitor + si-FSCN1 plasmids were constructed by Shanghai Sangon Biotech (Shanghai), Shanghai, China.

24 h before transfection, cells were inoculated into a 6-well plate. When they reached 30%–50% confluence, cells were transfected with different plasmids using Lipofectamine 2000 (11668-019, Invitrogen, New York, CA, USA) based on the instructions. The cells of third generation transfected with different plasmids were seeded in a 24-well plate and divided into different groups: blank group for IncRNA PVT1 (EC cells transfected with 0.4 pmol/\(\mu\)L blank plasmid), the IncRNA PVT1 mimic group (transfected with 0.4 pmol/\(\mu\)L...
IncRNA PVT1 mimic plasmid), the NC group for IncRNA PVT1 (transfected with 0.4 pmol/μL IncRNA PVT1 mimic negative meaningless sequences), the si-IncRNA PVT1 group (transfected with 0.4 pmol/μL si-IncRNA PVT1 plasmid), the blank group for miR-145 (transfected with 0.4 pmol/μL miR-145 negative nonsense sequences), the miR-145 mimic group (transfected with 0.4 pmol/μL miR-145 mimic plasmid), the NC group for miR-145 (transfected with 0.4 pmol/μL miR-145 inhibitor nonsense sequences), the miR-145 inhibitor group (transfected with 0.4 pmol/μL miR-145 inhibitor plasmid), the si-FSCN1 group (transfected with 0.4 pmol/μL si-FSCN1 plasmid), and the miR-145 inhibitor + si-FSCN1 group (transfected with 0.4 pmol/μL miR-145 inhibitor + si-FSCN1 plasmid).

RNA Isolation and Quantitation

miRNeasy Mini Kit (217004, Qiagen, Valencia, CA, USA) was adopted to extract RNA from tissues and cells after transfection. The primer sequences for IncRNA PVT1, miR-145, FSCN1, and EC related genes were designed and then synthesized by Takara, Dalian, China (Table 1). Then RNA was reversely transcribed into cRNA using the PrimeScript RT kit (RR836A, Takara, Dalian, China) according to the instructions. Then fluorescence qPCR was conducted according to the instructions of SYBR Premix Ex TaqTM II kit (RR820A, Takara, Dalian, China) using ABI7500 qRT-PCR instrument (7900, ABI Company, Oyster Bay, NY, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was taken as internal control, relative transcriptional level of target genes were calculated as follows: ΔΔCt = ΔCt (model group) − ΔCt (normal group), ΔCt = Ct (target gene) − Ct (internal control).

Western Blot Analysis

Radioimmunoprecipitation (RIPA) kit (R0010, Beijing Solabio Life Sciences, Beijing, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group. Bicinchoninic acid (BCA) kit (G3522-1, Guangzhou Jepes Biotechnology, China) was taken to extract total proteins from left lung tissues in each group.

FISH

Separation of cytoplasm and nucleus: transfected cells were collected. Then the cells were transferred into a 1.5 mL EP tube and centrifuged...
for 2–3 min. After the supernatant was discarded, the pellet was dissolved in pre-cooled CER I by the maximum rotational speed vortex and lysed on ice for 10 min, then pre-cooled CER II was added, followed by vortex at the maximum rotational speed for 5 s. Then the samples were incubated on ice for 1 min. Supernatant containing cytoplasm was absorbed into a new centrifuge tube and preserved at −80°C for further use. The pellets were washed and precipitated by PBS three times, added with pre-cooled CER, followed by vortex at the maximum rotational speed for 15 s. Then the samples were incubated on ice for 40 min, followed by vortex for 15 s. The samples were centrifuged for 10 min at 4°C, and the supernatant containing nuclear components was transferred into a new EP tube and preserved at −80°C for further use.

In situ hybridization was as follows: on the first day, the slide was dried at 50°C for 15–30 min, then fixed in diethy pyrocarbonate (DEPC)-4% PFA (polytetrafluoro ethylene) for 20 min. The slide was rinsed once in the 1× DEPC-PBS, and then bathed in the 1× DEPC-PBS for 5 min. The slide was incubated with acetic acid (0.1 M RNase-free triethylamine [TEA]) for 10 min, rinsed once in the 1× DEPC-PBS, and re-rinsed in the 1× DEPC-PBS for 5 min. Every slice was prehybridized with 200 μL pre-hybridization solution in a hybrid box for 1 h. The hybrid box consisted of 50% 2× SSC and 50% formamide. Slices were then hybridized with RNA probe (0.1–0.2 ng/μL) overnight at 65°C for 12–16 h. On the second day, the slice was bathed in the pre-heated 0.2× SSC for three times (20 min per time), re-bathed in 0.2× SSC for 5 min, in Buffer B1 two times (5 min per time). Then it was enclosed by Buffer B2 for 1 h and incubated with anti-digoxigenin-alkaline phosphatase (anti-DIG-AP Fab antibody) (diluted by Buffer B2 at 1:5,000) overnight at 4°C. On the third day, the slide was bathed in Buffer B1 three times (20 min per time), and then sliced evenly by Buffer B3 at room temperature two times (5–10 min per time). The slices were incubated with newly configured 5-bromo-4-chloro-3-indolyl phosphate/nitroblue.
tetrazolium (BCIP/NBT) chromogenic liquid in dark for 3–24 h, which was ended by double-distilled water (ddH₂O).

**Dual-Luciferase Reporter Assay**

Bioinformatic website RNA22 was used to analyze the target relationship between lncRNA PVT1 and miR-145 and dual-luciferase reporter assay was carried to verify whether miR-145 was a target of lncRNA PVT1 and whether FSCN1 was a target gene of miR-145. Full-length lncRNA PVT1 was ligated into pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega Corporation, Madison, WI, USA) to construct WT pmirGLO-lncRNA. pmirGLO-lncRNA mutant was also constructed in which the binding sites of miR-145 were mutated. Target sequence and mutation sequence were designed and transfected. And 48 h after transfection, cells were collected and dual luciferase reporter assay was performed based on instructions of dual-luciferase detection kit (D0010, Beijing Solabio Life Sciences, Beijing, China). Fluorescence intensity was measured by Glomax20/20 luminometer fluorescence detector in Promega Corporation, Madison, WI, USA (Shanxi Zhongmei Biotechnology, Shanxi, China).

**RNA Pull-Down and RIP Assay**

lncRNA PVT1 and lncRNA PVT1-Mut fragments were synthesized by Shanghai Sangon Biotech (Shanghai China) in vitro, which were then transcribed using T7 RNA polymerase (Promega Corporation, Madison, WI, USA) and labeled by Biotin RNA Labeling Mix biotin. One μg marked RNA was heated to 95°C in RNA structure buffer (10 mmol L⁻¹ Tris pH7, 0.1 mmol L⁻¹ KCl, 10 mmol L⁻¹ MgCl₂) for 2 min. Then the RNA was incubated on ice for 3 min and at room temperature for 30 min. Cell lysate of SMMC-7721 cells was incubated with 400 ng marked RNA and 500 μL RIP buffer (Millipore, Billerica, MA, USA) for 1 h and then incubated with 50 μL Streptavidin agarose beads (Invitrogen, Carlsbad, California, USA) for 1 h. The tube was washed with RIP buffer 5 times. Scrubbing solution was collected and qRT-PCR and western blot were conducted.

**MTT Assay**

When cell density reached 80% after transfection, cells were detached by 0.25% trypsin and then made into single cell suspension. After counting, cells were seeded into a 96-well plate at 3 × 10⁵ – 6 × 10⁵ cells/well, 0.2 mL/well in an incubator. Six duplicated wells were set. 24 h, 48 h, and 72 h after, culture medium containing 10% MTT (5 g/L) (GD-Y1317, Goodox Biotechnology, Shanghai, Beijing) was added, and cells were cultured for 4 h. The supernatant was sucked out. Each well was incubated with 100 μL dimethyl sulfoxide (DMSO) (D8789-100ML, Sigma-Aldrich Chemical Company, St. Louis, MO, USA) for 10 min to dissolve the formazan crystal produced by living cells. Optical density (OD) at 490 nm was measured by enzymatic marker (Nanjing Detie Experimental Equipment) for each well. Cell viability curve graph was made with time point as abscissa and OD value as ordinate.

**Scratch Test**

48 h after transfection, cells were inoculated into a 6-well plate. After cell attachment, culture medium was changed into serum-free Dulbecco’s modified Eagle medium (DMEM) (https://www.thermofisher.com). When cell confluence reached 90%–100%, 10 μL pipette was used to scratch on the bottom of the 6-well plate vertically. Each well was scratched about 4–5 strips with same width. The scratched cells were washed away and the plate was put into the
incubator for further culture. Migration distance of cell scratch region was observed with an inverted microscope after scratch for 24 h. Photographs of several randomly selected views were obtained. Three duplicated wells were set.

Transwell Assay

48 h after transfection, cells were starved for 24 h in serum-free medium and then detached and washed by PBS twice. Cells were resuspended with serum-free medium Opti-MEMI (31985008, Nanjing Senbega Biotechnology, Jiangsu, China) containing 10 g/L BSA. Cell density was adjusted to $3 \times 10^4$ cells/mL. Transwell chambers were put into the 24-well plate. The apical chamber of the bottom membrane of Transwell chamber was coated with Matrigel (1:8, 40111ES08, Shanghai Yisheng Biotechnology, Shanghai, China). After cells in each group were detached normally, they were rinsed by PBS twice and resuspended with RPMI 1640 medium containing 20% FBS. 600 μL RPMI 1640 medium containing 20% FBS was added into the basolateral chamber. When cells were normally cultured for 24 h, Transwell chamber was taken out. Inner cells of apical chamber were erased with a cotton bud, fixed for 15 min with 4% paraformaldehyde, dyed with 0.5% crystal violet solution for 15 min. Photographs of 5 random visuals were obtained using an inverted microscope (XDS-800D, Shanghai Cai Kang Optical Instrument, China). Cells passed through membrane were counted. Three duplicated wells were set in each group.

Figure 11. Apoptosis and Transition of Cell Cycle from G1 Phase to S Phase Were Inhibited with Silencing miR-145 and IncRNA PVT1

(A and B) Cell cycle was determined by PI staining. (C and D) Apoptosis was determined by Annexin V-PI double staining. Statistical results of graph B were count data and expressed as mean ± standard deviation. Variance analysis measured repeatedly was adopted to analyze the data. The experiment was repeated three times. Statistical results of (B) were count data and expressed as mean ± standard deviation. One-way ANOVA was adopted to analyze the data. The experiment was repeated three times; *, versus the blank group, p < 0.05; #, versus the NC group, p < 0.05; miR-145, microRNA-145; one-way ANOVA, one-way analysis of variance; IncRNA, long non-coding RNA; PVT1, plasmacytoma variant translocation 1 gene; NC, negative control.
After transfection for 48 h, cells were collected and washed by pre-cooled equilibrium salt solution twice and then centrifuged at 179 × g for 5 min, and supernatant was discarded. Cells were fixed with pre-cooled 70% ethyl alcohol overnight at 4°C. After the cells were washed by balanced salt solution PBS, they were centrifuged at 179 × g for 5 min. Then 10 μL RNase enzyme was added into the cells and incubated at 37°C for 5 min. The cells were stained with 1% PI (40710ES03, Shanghai Qiandun Biotechnology) in dark for 30 min. Cells were put into the flow cytometry (FACSCalibur, BD, FL, NJ, USA) and the cell cycle was recorded and measured according to red fluorescence at 488 nm.

After transfection for 48 h, cells were collected and washed with pre-cooled PBS. Apoptosis was determined by Annexin-V-fluorescein isothiocyanate (FITC)/PI apoptosis detection kit (CA1020, Beijing Solabio Life Sciences, Beijing, China). Cells were washed by binding buffer and incubated with mixed solution of Annexin-V-FITC and binding buffer at 1:40 for 30 min, and then incubated with mixed solution of PI and binding buffer at 1:40 for 15 min. Apoptosis was assayed using flow cytometry.

**Flow Cytometry**

**Tumor Formation in Nude Mice**

Nude mice were injected with EC cells subcutaneously: 50 BLAB/CA nude mice weighing 16–20 g and aged 6–8 weeks were randomly grouped into 10 groups: 5 IncRNA PVT1 related groups: IncRNA PVT1: the blank, NC, IncRNA PVT1 mimic and si-lncRNA PVT1 groups; and 5 miR-145 related groups: the blank, NC, miR-145 mimic, miR-145 inhibitor, and miR-145 inhibitor + siPVT1 groups.

![Figure 12. Inhibiting Expression of IncRNA PVT1 Suppressed the Development of EC](image)

(A, B, and C) The weight and volume of tumor in nude mice with silencing IncRNA PVT1. (D, E, and F) The weight and volume of tumor in nude mice with overexpressing miR-145. Each analytic result was the count data and expressed as mean ± standard deviation. One-way ANOVA was adopted to analyze the data. The experiment was repeated three times; *, versus the blank group, p < 0.05; #, versus the NC group, p < 0.05; IncRNA, long non-coding RNA; miR-145, microRNA-145; one-way ANOVA, one-way analysis of variance; PVT1, plasmacytoma variant translocation 1 gene; NC, negative control.

![Figure 13. Mechanism Model of IncRNA PVT1 Involved in EC](image)

IncRNA PVT1 can specifically compete with miR-145, and silencing of IncRNA PVT1 can upregulate the expression of miR-145 and downregulate FSCN1 expression, thus inhibit invasion, metastasis, survival, viability, and promote apoptosis of esophageal cancer cells.
### Table 1. The Primer Sequence of qRT-PCR

| Gene         | Sequence (5’-3’)                                                                 |
|--------------|----------------------------------------------------------------------------------|
| IncRNA PVT1  | F: 5'-TGAGAAGCTGTCCATTACGGACC-3’                                                |
|              | R: 5'-AGGACCAAGACGTGGCCT-3’                                                      |
| miR-145      | F: 5’-ACACTCCAGGTGGGTCCAGTTTCCCAGGAA-3’                                         |
|              | R: 5’-CTCAACTGGTGGTGTGGAGA-3’                                                    |
| FSCN1        | F: 5’-ACAGCAAGGAGACTCAG-3’                                                       |
|              | R: 5’-CCACCGTCAGATTTT-3’                                                         |
| CD147        | F: 5’-GACGACCACTGGGAGATGTA-3’                                                    |
|              | R: 5’-GGGAGGAAACTCAAGAAGAAC-3’                                                   |
| MTA1         | F: 5’-CAGCTCAGAGCAAGACCAACCG-3’                                                  |
|              | R: 5’-TGTCGGTGGTTTGCCAG-3’                                                       |
| VEGFR2       | F: 5’-GAAGAGTGCACGCAAGGACG-3’                                                    |
|              | R: 5’-CTGCCGACTTTGTGACCCGT-3’                                                    |
| Bax          | F: 5’-CCGAGAAGTCCTTTCCTCGAG-3’                                                   |
|              | R: 5’-CCAGCCCATGATGTTCTGAT-3’                                                    |
| Bcl-2        | F: 5’-GGTTGGGTCATGTTGGTGG-3’                                                     |
|              | R: 5’-GGTTCAAGCTACAGTCATCC-3’                                                    |
| GAPDH        | F: 5’-GGAGGAGATCCCTCCAAAT-3’                                                     |
|              | R: 5’-GGCTTTGTCATCATCTCTAGG-3’                                                   |

100 µl cell suspension was subcutaneously injected into right axilla of each nude mice. Tumorogenesis in nude mice was observed once a week. Weight was measured by an electronic balance and volume was measured by vernier calipers. The changes of spirit, diet, and activities of nude mice were also observed. Nude mice were executed at the fourth week. Tumor issues were separated, and tumor weight and volume were measured (volume = 1/2 × length × width²). Tumor tissues were soaked in 4% polyaldehyde at room temperature or at 4°C for subsequent use.

### Statistical Analysis

Statistical analyses were conducted using SPSS 21.0 (IBM, Armonk, NY, USA). The count data were presented as the mean ± standard deviation. Independent sample t test was used for comparison between two groups, and one-way analysis of variance (ANOVA) was adopted to analyze comparison between multiple groups. p < 0.05 was considered statistically significant.

### ACKNOWLEDGMENTS

The authors want to show their appreciation to reviewers for their helpful comments. This study was supported by “Ubiquitin-proteasome pathway gene SNPs and paclitaxel sensitivity in advanced esophageal squamous cell carcinoma” (grant number 81201954).

### REFERENCES

1. Shibuya, D., Terayama, M., Yamada, K., Hagisawa, T., Oyama, C., Tamura-Nakano, M., Igar, T., Yokoi, C., Soma, D., Nohara, K., et al. (2018). Clinicopathological significance of cystatin A expression in progression of esophageal squamous cell carcinoma. Medicine (Baltimore) 97, e0357.

2. He, F., Liu, C., Zhang, R., Han, Z., Li, Y., Zhang, N., and Zheng, L. (2018). Association between the Glutathione-S-transferase T1 null genotype and esophageal cancer susceptibility: a meta-analysis involving 11,163 subjects. Oncotarget 9, 15111–15121.

3. Zhao, W., Liu, L., and Xu, S. (2018). Intakes of citrus fruit and risk of esophageal cancer: A meta-analysis. Medicine (Baltimore) 97, e0018.

4. Nayan, N., Bhattacharya, M., Jagtap, V.K., Kalita, A.K., Sunku, R., and Roy, P.S. (2018). Standard-dose versus high-dose radiotherapy with concurrent chemotheromotherapy in esophageal cancer: A prospective randomized study. South Asian J. Cancer 7, 27–30.

5. Zhou, C., Ma, J., Su, M., Shao, D., Zhao, J., Zhao, T., Song, Z., Meng, Y., and Jiao, P. (2018). Down-regulation of STAT3 induces the apoptosis and G1 cell cycle arrest in esophageal carcinoma ECA109 cells. Cancer Cell Int. 18, 53.

6. Yu, Z., Li, S., Liu, D., Liu, L., He, J., Huang, Y., Xu, S., Mao, W., Tan, Q., Chen, C., et al. (2018). Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients. J. Thorac. Dis. 10, 1050–1057.

7. Song, Y., Zhao, Y., Ding, X., and Wang, X. (2018). microRNA-532 targeting PIK3/Akt signaling pathway to inhibit colorectal cancer progression by directly targeting mTOR pathway. Oncotarget 9, 435–449.

8. Derouet, M.F., Dalpo, E., Wu, L., Zehong, G., Conner, J., Keshavjee, S., de Perrot, M., Waddell, T., Elmova, E., Yeung, J., and Darling, G.E. (2018). miR-145 expression enhances integrin expression in SK-GT-4 cell line by down-regulating c-Myc expression. Oncotarget 9, 15198–15207.

9. Johannessen, C., Moi, L., Kiselev, Y., Pedersen, M.I., Dalen, S.M., Braaten, T., and Buslund, L.T. (2017). Expression and function of the miR-143-145 cluster in vitro and in vivo in human breast cancer. PLoS ONE 12, e0186658.

10. Mataki, H., Seki, N., Mizuno, K., Nobata, N., Kamikawaji, K., Kumanoto, T., Koshizuka, K., Goto, Y., and Inoue, H. (2016). Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget 7, 72084–72098.

11. Yu, Y., Nanga-Makker, P., Farhana, L., and Majumdar, A.P.N. (2017). A novel mechanism of IncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol. Cancer 16, 155.

12. Zeng, J.F., Ma, X.Q., Wang, L.P., and Wang, W. (2017). MicroRNA-145 exerts tumour-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J. Gastroenterol. 23, 2337–2345.

13. Du, Y., Li, J., Xu, T., Zhou, D.D., Zhang, L., and Wang, X. (2017). MicroRNA-145 induces apoptosis of glioma cells by targeting BNP13 and Notch signaling. Oncotarget 8, 61510–61527.

14. Cui, X.B., Li, S., Li, T.T., Peng, H., Jin, T.T., Zhang, S.M., Liu, C.X., Yang, L., Shen, Y.Y., Li, S.G., et al. (2016). Targeting oncogenic PLCE1 by miR-145 impairs tumor progression and suppresses its maturation process in colon cancer cells. Mol. Cancer 15, 2345–2355.
proliferation and metastasis of esophageal squamous cell carcinoma. Oncotarget 7, 1777–1795.
15. Hu, C.E., Du, P.Z., Zhang, H.D., and Huang, G.J. (2017). Long Noncoding RNA CRNDE Promotes Proliferation of Gastric Cancer Cells by Targeting miR-145. Cell. Physiol. Biochem. 42, 13–21.
16. Chai, J., Guo, D., Ma, W., Han, D., Dong, W., Guo, H., and Zhang, Y. (2018). A feedback loop consisting of RUNX2/LncRNA-PVT1/miR-455 is involved in the progression of colorectal cancer. Am. J. Cancer Res. 8, 538–550.
17. Liu, H.T., Fang, L., Cheng, Y.X., and Sun, Q. (2016). LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med. 5, 3512–3519.
18. Liu, Z., and Zhang, H. (2017). LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget 8, 64273–64282.
19. Xue, M., Fang, H., Li, X., Li, H., Pan, J., and Chen, W. (2016). Long non-coding RNA urthelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 107, 18–27.
20. Zhang, Y., Lu, Y., Zhang, C., Huang, D., Wu, W., Zhang, Y., Shen, J., Cai, Y., Chen, W., and Yao, W. (2018). FSCN-1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int. J. Oncol. 52, 1455–1464.
21. Zhao, H., Kang, X., Xia, X., Wo, L., Gu, X., Hu, Y., Xie, X., Chang, H., Lou, L., and Shen, X. (2016). miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am. J. Transl. Res. 8, 3106–3114.
22. Liu, X., Wang, Z., Zhang, G., Zhu, Q., Zeng, H., Wang, T., Gao, F., Qi, Z., Zhang, J., and Wang, R. (2018). Overexpression of asparaginyl endopeptidase is significant for esophageal carcinoma metastasis and predicts poor patient prognosis. Oncol. Lett. 15, 1229–1235.
23. Qi, B., Wang, Y., Chen, Z.J., Li, X.N., Qi, Y., Yang, Y., Cui, G.H., Guo, H.Z., Li, W.H., and Zhao, S. (2017). Down-regulation of miR-30d-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway. World J. Gastroenterol. 23, 7965–7977.
24. Pan, Z., Mao, W., Bao, Y., Zhang, M., Su, X., and Xu, X. (2016). The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer. Cancer Med. 5, 2442–2447.
25. Chen, X., Gong, J., Zeng, H., Chen, N., Huang, R., Huang, Y., Nie, L., Xu, M., Xia, J., Zhao, F., et al. (2010). MicroRNA145 targets BNP1P3 and suppresses prostate cancer progression. Cancer Res. 70, 2728–2738.
26. Ling, D.J., Chen, Z.S., Zhang, Y.D., Liao, Q.D., Feng, J.X., Zhang, X.Y., and Shi, T.S. (2015). MicroRNA-145 inhibits lung cancer cell metastasis. Mol. Med. Rep. 11, 3108–3114.
27. Letelier, P., Garcia, P., Leal, P., Alvarez, H., Bi, C., Lopez, J., Castillo, J., Brebi, P., and Rosa, J.C. (2014). miR-1 and miR-145 act as tumor suppressor microRNAs in gall-bladder cancer. Int. J. Clin. Exp. Pathol. 7, 1849–1867.
28. Liu, B., Pan, C.F., Yao, G.L., Wei, K., Xia, Y., and Chen, Y.J. (2018). The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. Cancer Cell Int. 18, 38.
29. Wu, Q., Yang, F., Yang, Z., Fang, Z., Fu, W., Chen, W., Liu, X., Zhao, J., Wang, Q., Hu, X., and Li, L. (2017). Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1. Oncotarget 8, 101865–101875.
30. Shang, M., Wang, X., Zhang, Y., Gao, Z., Wang, T., and Liu, R. (2018). LncRNA ROR promotes metastasis and invasion of esophageal squamous cell carcinoma by regulating miR-145/FSCN1. OncoTargets Ther. 11, 639–649.
31. Akanuma, N., Hoshino, I., Akutsu, Y., Murakami, K., Isozaki, Y., Maruyama, T., Yusup, G., Qin, W., Toyozumi, T., Takahashi, M., et al. (2014). MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br. J. Cancer 110, 189–198.
32. Ping, G., Xiong, W., Zhang, L., Li, Y., Zhang, Y., and Zhao, Y. (2018). Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am. J. Transl. Res. 10, 138–149.
33. Holmes, K., Roberts, O.L., Thomas, A.M., and Cross, M.J. (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell. Signal. 19, 2003–2012.
34. Sureban, S.M., May, R., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S.A., Pantazis, P., Rao, C.V., Postier, R.G., and Houchen, C.W. (2013). DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS ONE 8, e73940.
35. Liu, J., Xia, J., Zhang, Y., Fu, M., Gong, S., and Guo, Y. (2017). Associations between the expression of MT1A and VEGF-C in esophageal squamous cell carcinoma with lymph angiogenesis and lymph node metastasis. Oncol. Lett. 14, 3275–3281.
36. Zhang, T., Li, H., Zhang, Y., Wang, P., Bian, H., and Chen, Z.N. (2018). Expression of proteins associated with epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Oncol. Lett. 15, 3042–3048.
37. Zhang, Y., and Lin, Q. (2015). MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. Int. J. Clin. Exp. Med. 8, 8794–8802.
38. Chang, L., Yuan, Z., Shi, H., Bian, Y., and Guo, R. (2017). miR-145 targets the SOX11 3’UTR to suppress endometrial cancer growth. Am. J. Cancer Res. 7, 2305–2317.
39. Huang, H., Xu, Y., Guo, Z., Chen, X., Ji, S., and Xu, Z. (2018). MicroRNA-133b inhibits cell proliferation and promotes apoptosis by targeting cullin 4B in esophageal squamous cell carcinoma. Exp. Ther. Med. 15, 3743–3750.
40. Li, Y., Chen, D., Gao, X., Li, X., and Shi, G. (2017). LncRNA NEAT1 Regulates Cell Viability and Invasion in Esophageal Squamous Cell Carcinoma through the miR-129/CTBP2 Axis. Dis. Markers 2017, 5314649.
41. Guo, L., Bai, H., Zou, D., Hong, T., Liu, J., Huang, J., He, P., Zhou, Q., and He, J. (2014). The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J. Exp. Clin. Cancer Res. 33, 99.
42. Fujita, A., Sato, J.R., Rodrigues, Lde.O., Ferreira, C.E., and Sogayar, M.C. (2006). Evaluating different methods of microarray data normalization. BMC Bioinformatics 7, 469.
43. Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3. Published online February 11, 2004. https://doi.org/10.2202/1544-6115.1027.
44. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140.
45. Mutus, B., Wagner, J.D., Talpa, C.J., Dimmock, J.R., Phillips, O.A., and Reid, R.S. (1989). 1-p-chlorophenyl-4,4-dimethyl-5-diethylamin-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiol but reversibly with small molecular weight thiols. Anal. Biochem. 177, 237–243.